fbpx Skip to main content

Dealing with diversity and adequate representation in Alzheimer’s Disease clinical trials is especially pressing due to the large number of individuals with this disease and the very high failure rate (99.6%) of new drugs. This literature review, published in the Journal of Alzheimer’s Disease, analyzes the racial and sex-based disparities in Alzheimer’s clinical trials over the past 20 years.

The researchers focused on Indigenous populations in the United States and Canada, although enrollment rates and their effects are also described at a more general level. Among the many factors described, they note that poverty and education levels among Indigenous populations can make forms of cognitive decline less likely to be treated. Multiple other factors such as lack of trust and access to trials are analyzed in detail.

The researchers concluded that a variety of stressors experienced by Indigenous communities might contribute to their higher rates of Alzheimer’s Disease. They note that a multi-pronged approach must be used to hone in on individual barriers to trial participation to significantly impact the current low participation rates among Indigenous people [1].


[1] Olson, N. L., & Albensi, B. C. (2020). Race- and Sex-Based Disparities in Alzheimer’s Disease Clinical Trial Enrollment in the United States and Canada: An Indigenous Perspective. Journal of Alzheimer’s Disease Reports, 4(1), 325–344. https://doi.org/10.3233/adr-200214

You May Also Like::  How the Integration of E-path Reporting With Clinical Trial Matching Can Help Improve Recruitment of Racially Diverse Prostate Cancer Patients